Haemonetics (HAE) Competitors $55.10 -0.13 (-0.24%) Closing price 08/27/2025 03:59 PM EasternExtended Trading$55.08 -0.02 (-0.03%) As of 08/27/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, ALGN, and MMSIShould you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Align Technology (ALGN), and Merit Medical Systems (MMSI). These companies are all part of the "medical" sector. Haemonetics vs. Its Competitors DexCom HealthEquity Lantheus Insulet Quanterix SiBone Penumbra Zimmer Biomet Align Technology Merit Medical Systems DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has stronger valuation & earnings, DXCM or HAE? DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.03B7.43$576.20M$1.4453.04Haemonetics$1.36B1.95$167.68M$3.2716.85 Does the media prefer DXCM or HAE? In the previous week, DexCom had 17 more articles in the media than Haemonetics. MarketBeat recorded 37 mentions for DexCom and 20 mentions for Haemonetics. DexCom's average media sentiment score of 1.25 beat Haemonetics' score of 1.24 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 23 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DXCM or HAE more profitable? DexCom has a net margin of 13.29% compared to Haemonetics' net margin of 12.14%. DexCom's return on equity of 30.41% beat Haemonetics' return on equity.Company Net Margins Return on Equity Return on Assets DexCom13.29% 30.41% 10.08% Haemonetics 12.14%26.64%9.32% Do analysts rate DXCM or HAE? DexCom currently has a consensus price target of $99.89, indicating a potential upside of 30.79%. Haemonetics has a consensus price target of $85.18, indicating a potential upside of 54.61%. Given Haemonetics' higher possible upside, analysts plainly believe Haemonetics is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95Haemonetics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do institutionals & insiders believe in DXCM or HAE? 97.8% of DexCom shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 1.8% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, DXCM or HAE? DexCom has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. SummaryDexCom beats Haemonetics on 13 of the 17 factors compared between the two stocks. Get Haemonetics News Delivered to You Automatically Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HAE vs. The Competition Export to ExcelMetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$2.66B$10.71B$5.79B$21.25BDividend YieldN/A1.86%3.95%3.53%P/E Ratio16.8521.2030.8329.20Price / Sales1.9531.87460.9753.33Price / Cash7.6624.9437.7623.64Price / Book3.013.5010.185.36Net Income$167.68M$210.11M$3.26B$996.59M7 Day Performance1.94%4.70%2.79%2.99%1 Month Performance-26.20%11.78%3.95%2.88%1 Year Performance-26.62%-6.50%44.12%12.54% Haemonetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HAEHaemonetics4.9524 of 5 stars$55.10-0.2%$85.18+54.6%-28.2%$2.66B$1.36B16.853,023Trending NewsAnalyst RevisionDXCMDexCom4.9621 of 5 stars$80.82-0.2%$99.89+23.6%+5.7%$31.74B$4.03B56.1310,300Positive NewsHQYHealthEquity4.3603 of 5 stars$89.53-0.4%$118.55+32.4%+15.3%$7.77B$1.20B65.353,120News CoveragePositive NewsUpcoming EarningsLNTHLantheus4.7734 of 5 stars$55.97+3.3%$105.50+88.5%-47.9%$3.68B$1.52B14.89700Analyst RevisionPODDInsulet4.4108 of 5 stars$323.07+0.6%$330.71+2.4%+73.6%$22.62B$2.07B98.203,900Positive NewsQTRXQuanterix2.2997 of 5 stars$4.95+8.3%$11.75+137.4%-65.6%$212.35M$137.42M-2.72460SIBNSiBone4.265 of 5 stars$15.54+0.5%$23.67+52.3%+0.7%$666.96M$167.18M-27.75350News CoveragePositive NewsPENPenumbra4.7586 of 5 stars$255.35+0.9%$300.47+17.7%+31.9%$9.87B$1.19B67.914,500ZBHZimmer Biomet4.7049 of 5 stars$102.67-0.1%$111.44+8.5%-6.8%$20.35B$7.68B24.9817,000Positive NewsDividend AnnouncementALGNAlign Technology4.9472 of 5 stars$144.94+1.8%$215.00+48.3%-39.9%$10.32B$4.00B24.4420,945MMSIMerit Medical Systems4.4939 of 5 stars$86.16+0.8%$107.00+24.2%-3.2%$5.06B$1.43B43.747,400News CoveragePositive NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies DexCom Alternatives HealthEquity Alternatives Lantheus Alternatives Insulet Alternatives Quanterix Alternatives SiBone Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HAE) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access